Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T).

Authors

David I. Quinn

University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

David I. Quinn , Stephen J. Freedland , Ronald F. Tutrone , David G. McLeod , Nadeem Anwar Sheikh , Nancy N. Chang , A. Oliver Sartor , Elisabeth I. Heath

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

Interpreting survival outcomes for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (SIP-T) with number needed to treat to benefit (NNTB).

First Author: Kelvin A. Moses

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED.

First Author: Nicholas J. Vogelzang

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).

First Author: Susan Halabi

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Association between PET-based TheraP eligibility and ¹⁷⁷Lu-PSMA-617 (LuPSMA) outcomes in VISION-eligible patients with metastatic castration-resistant prostate cancer (mCRPC).

First Author: Ridvan Arda Demirci